FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wim Kruit

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Alexander M M Eggermont; Gaetan de Schaetzen; Reinhard Dummer; Wim H J Kruit; Jeremy Marsden; Poulam M Patel; Cornelis J A Punt; Caroline Robert; François Salès; mario santinami; Dirk Schadendorf; Alan Spatz; Stefan Suciu; Alessandro Testori; Ulrich Keilholz
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
M G Bouwhuis; Stefan Suciu; Wim H J Kruit; F Salès; Konstantin Stoitchkov; Poulam Patel; V Cocquyt; J Thomas; D Liénard; A M M Eggermont; Ghanem Ghanem
Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
Marna G Bouwhuis; Stefan Suciu; Alessandro Testori; Wim H J Kruit; François Salès; Poulam Patel; Cornelis J A Punt; mario santinami; A Spatz; Timo L M ten Hagen; Alexander M M Eggermont
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wim Kruit (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Alexander M M Eggermont; Gaetan de Schaetzen; Reinhard Dummer; Wim H J Kruit; Jeremy Marsden; Poulam M Patel; Cornelis J A Punt; Caroline Robert; François Salès; mario santinami; Dirk Schadendorf; Alan Spatz; Stefan Suciu; Alessandro Testori; Ulrich Keilholz
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(31):3810-8.
2011: M G Bouwhuis; Stefan Suciu; Wim H J Kruit; F Salès; Konstantin Stoitchkov; Poulam Patel; V Cocquyt; J Thomas; D Liénard; A M M Eggermont; Ghanem Ghanem
Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
European journal of cancer (Oxford, England : 1990) 2011;47(3):361-8.
2010: Marna G Bouwhuis; Stefan Suciu; Alessandro Testori; Wim H J Kruit; François Salès; Poulam Patel; Cornelis J A Punt; mario santinami; A Spatz; Timo L M ten Hagen; Alexander M M Eggermont
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(14):2460-6.
2010: Alexander M M Eggermont; Marna G Bouwhuis; Wim H J Kruit; Alessandro Testori; Timo L M ten Hagen; Antoine Yver; Christine Xu
Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
Cancer chemotherapy and pharmacology 2010;65(4):671-7.
2009: Alberto Fusi; Sandra Collette; Antonia Busse; Stefan Suciu; Anika Rietz; mario santinami; Wim H J Kruit; Alessandro Testori; Cornelis J A Punt; Angus G Dalgleish; Alan Spatz; Alexander M M Eggermont; Ulrich Keilholz
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
European journal of cancer (Oxford, England : 1990) 2009;45(18):3189-97.
2009: Durk Fekkes; Arthur R Van Gool; Marjolein Bannink; Stefan Sleijfer; Wim H J Kruit; Bronno van der Holt; Alexander M M Eggermont; Michiel W Hengeveld; Gerrit Stoter
Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy.
Amino acids 2009;37(4):703-8.
2009: Marna G Bouwhuis; Stefan Suciu; Sandra Collette; Steinar Aamdal; Wim H J Kruit; Lars Bastholt; Ulrika Stierner; François Salès; Poulam Patel; Cornelis J A Punt; Micaela Hernberg; Alain Spatz; Timo L M ten Hagen; Johan Hansson; Alexander M M Eggermont
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Journal of the National Cancer Institute 2009;101(12):869-77.
2008: Arthur R Van Gool; Robert Verkerk; Durk Fekkes; Marjolein Bannink; Stefan Sleijfer; Wim H J Kruit; Bronno van der Holt; Simon Scharpé; Alexander M M Eggermont; Gerrit Stoter; Michiel W Hengeveld
Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Psychiatry and clinical neurosciences 2008;62(5):597-602.
2008: Alexander M M Eggermont; Stefan Suciu; mario santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena MUSAT; Alain Spatz; Ulrich Keilholz
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Lancet 2008;372(9633):117-26.
2008: Arthur R Van Gool; R Verkerk; Durk Fekkes; Stefan Sleijfer; Marjolein Bannink; Wim H J Kruit; B van der Holt; S Scharpé; A M M Eggermont; Gerrit Stoter; M W Hengeveld
Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2008;28(5):283-6.
2008: Wim H J Kruit
[Viewpoint of the Dutch Melanoma Working Group regarding sentinel lymph node biopsy: prognostic but not therapeutic implications].
Nederlands tijdschrift voor geneeskunde 2008;152(10):574-6.
2008: P H M De Mulder; J B A G Haanen; S Sleijfer; Wim H J Kruit; J A Gietema; D J Richel; G Groenewegen; E E Voest; Alfons J M van den Eertwegh; S Osanto; R L H Jansen; Peter F A Mulders
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
Nederlands tijdschrift voor geneeskunde 2008;152(7):371-5.
2008: Marjolein Bannink; Wim H J Kruit; Arthur R Van Gool; Stefan Sleijfer; Bronno van der Holt; Alexander M M Eggermont; Gerrit Stoter; Michiel W Hengeveld
Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
Psychosomatics 2008;49(1):56-63.
2007: Henrik Schmidt; Stefan Suciu; Cornelis J A Punt; Martin Gore; Wim H J Kruit; Poulam Patel; Danielle Lienard; Hans von der Maase; Alexander M M Eggermont; Ulrich Keilholz
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(12):1562-9.
2007: Marjolein Bannink; Durk Fekkes; Arthur R Van Gool; Wim H J Kruit; Stefan Sleijfer; Bronno van der Holt; Alexander M M Eggermont; Gerrit Stoter; Michiel W Hengeveld
Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.
Neuropsychobiology 2007;55(3-4):225-31.
2007: Durk Fekkes; Marjolein Bannink; Wim H J Kruit; Arthur R Van Gool; Paul G H Mulder; Stefan Sleijfer; Alexander M M Eggermont; Gerrit Stoter
Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients.
Amino acids 2007;32(1):121-6.
2006: Cornelis J A Punt; Stefan Suciu; M A Gore; J Koller; Wim H J Kruit; Jose Thomas; Poulam Patel; Danielle Lienard; Alexander M M Eggermont; Ulrich Keilholz
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2991-5.
2006: Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):e20-2.
2005: Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Side effects of interferon-alpha therapy.
Pharmacy world & science : PWS 2005;27(6):423-31.
2005: Wim H J Kruit; Heidi H van Ojik; Vincent G Brichard; Bernard Escudier; Thierry Dorval; Brigitte Dréno; Poulam Patel; Nicolas van Baren; Marie-Françoise Avril; Sophie Piperno; Amir Khammari; Marguerite Stas; Gerd Ritter; Bernard Lethé; Danièle Godelaine; Francis Brasseur; Yi Zhang; Pierre van der Bruggen; Thierry Boon; Alexander M M Eggermont; Marie Marchand
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
International journal of cancer. Journal international du cancer 2005;117(4):596-604.
2005: Alexander M M Eggermont; Stefan Suciu; Rona MacKie; Wlodzimierz Ruka; Alessandro Testori; Wim H J Kruit; Cornelis J A Punt; Michelle Delauney; François Sales; Gerard Groenewegen; Dirk J Ruiter; Izabella Jagiello; Konstantin Stoitchkov; Ulrich Keilholz; Danielle Lienard
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Lancet 2005;366(9492):1189-96.
2005: Ulrich Keilholz; Cornelis J A Punt; Martin Gore; Wim H J Kruit; Poulam Patel; Danielle Lienard; Jose Thomas; Thomas M Proebstle; Alexander Schmittel; Dirk Schadendorf; Thierry Velu; Sylvie Negrier; Ulrich Kleeberg; Frederic Lehman; Stefan Suciu; Alexander M M Eggermont
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6747-55.
2005: J J E van Everdingen; H J van der Rhee; C C E Koning; O E Nieweg; Wim H J Kruit; Dorry Boll; D J Ruiter
[Guideline 'Melanoma' (3rd revision)].
Nederlands tijdschrift voor geneeskunde 2005;149(33):1839-43.
2005: Johanna E A Portielje; Wim H J Kruit; Anke J M Eerenberg; Martin Schuler; Alex Sparreboom; Cor H J Lamers; Jan W Gratama; Gerrit Stoter; Christoph Huber; C Erik Hack
Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.
Cancer immunology, immunotherapy : CII 2005;54(1):37-43.
2005: Marjolein Bannink; Wim H J Kruit; Arthur R Van Gool; Paul G H Mulder; Stefan Sleijfer; Alexander M M Eggermont; Gerrit Stoter; Durk Fekkes
Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients.
Progress in neuro-psychopharmacology & biological psychiatry 2005;29(1):109-14.
2004: Stefan Sleijfer; Wim H J Kruit; Gerrit Stoter
Thalidomide in solid tumours: the resurrection of an old drug.
European journal of cancer (Oxford, England : 1990) 2004;40(16):2377-82.
2004: Wim H J Kruit; Gerrit Stoter; Jan G M Klijn
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
Anti-cancer drugs 2004;15(9):843-7.
2004: Arthur R Van Gool; Heidi H van Ojik; Wim H J Kruit; Paul G H Mulder; Durk Fekkes; Marjolein Bannink; S Scharpé; Gerrit Stoter; Alexander M M Eggermont; M Maes; R Verkerk
Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2004;24(7):411-5.
2004: Arthur R Van Gool; Heidi H van Ojik; Wim H J Kruit; Marjolein Bannink; Paul G H Mulder; Alexander M M Eggermont; Gerrit Stoter; Durk Fekkes
Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations.
Anti-cancer drugs 2004;15(6):587-91.
2004: Cor H J Lamers; Stefan Sleijfer; Ralph A Willemsen; Reno Debets; Wim H J Kruit; Jan W Gratama; Gerrit Stoter
Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.
Journal of biological regulators and homeostatic agents 2004;18(2):134-40.
2004: Ivar Bleumer; A Knuth; Egbert Oosterwijk; R Hofmann; Z Varga; C Lamers; Wim H J Kruit; S Melchior; Carola Mala; S Ullrich; P H M De Mulder; Peter F A Mulders; J Beck
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.
British journal of cancer 2004;90(5):985-90.
2003: Arthur R Van Gool; Durk Fekkes; Wim H J Kruit; Paul G H Mulder; Timo L M ten Hagen; Marjolein Bannink; Michael Maes; Alexander M M Eggermont
Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients.
Psychiatry research 2003;119(1-2):125-32.
2003: Tero Kivelä; Stefan Suciu; Johan Hansson; Wim H J Kruit; Meri-Sisko Vuoristo; O Kloke; M Gore; Marjo Hahka-Kemppinen; Leena-Maija Parvinen; Eero J Kumpulainen; Yves Humblet; Seppo Pyrhönen
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1115-20.
2003: L Kloos; Peter A E Sillevis Smitt; C Wim Ang; Wim H J Kruit; Gerrit Stoter
Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma.
Journal of neurology, neurosurgery, and psychiatry 2003;74(4):507-9.
2003: Johanna E A Portielje; Jan W Gratama; Heidi H van Ojik; Gerrit Stoter; Wim H J Kruit
IL-12: a promising adjuvant for cancer vaccination.
Cancer immunology, immunotherapy : CII 2003;52(3):133-44.
2003: Arthur R Van Gool; Wim H J Kruit; Frederike K Engels; Gerrit Stoter; Marjolein Bannink; Alexander M M Eggermont
Neuropsychiatric side effects of interferon-alfa therapy.
Pharmacy world & science : PWS 2003;25(1):11-20.
2003: Z Varga; P de Mulder; Wim H J Kruit; Axel Hegele; R Hofmann; C Lamers; S Warnaar; Carola Mala; S Ullrich; P Mulders
A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.
Folia biologica 2003;49(2):74-7.
2003: Johanna E A Portielje; Cor H J Lamers; Wim H J Kruit; Alex Sparreboom; Reinder L H Bolhuis; Gerrit Stoter; Christoph Huber; Jan W Gratama
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):76-83.
2003: Marie Marchand; Cornelis J A Punt; Steinar Aamdal; Bernard Escudier; Wim H J Kruit; U Keilholz; L Håkansson; Nicolas van Baren; Yves Humblet; P Mulders; M-F Avril; Alexander M M Eggermont; C Scheibenbogen; J Uiters; Jantien Wanders; M Delire; Thierry Boon; Gerrit Stoter
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
European journal of cancer (Oxford, England : 1990) 2003;39(1):70-7.
2002: Ulrich Keilholz; Peter Martus; Cornelis J A Punt; Wim H J Kruit; G Mooser; Dirk Schadendorf; D Liénard; R Dummer; J Koller; C Voit; Alexander M M Eggermont
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.
European journal of cancer (Oxford, England : 1990) 2002;38(11):1501-11.
2002: TC Stam; A J G Swaak; Wim H J Kruit; Alexander M M Eggermont
Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b.
European journal of clinical investigation 2002;32 Suppl 1():79-83.
2002: M E L van der Burg; Ronald de Wit; Wim L J van Putten; A Logmans; Wim H J Kruit; Gerrit Stoter; Jaap Verweij
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.
British journal of cancer 2002;86(1):19-25.
2001: Johanna E A Portielje; Wim H J Kruit; Anke J M Eerenberg; M Schuler; Alex Sparreboom; C H Lamers; Reinder L H Bolhuis; Gerrit Stoter; Christoph Huber; C Erik Hack
Interleukin 12 induces activation of fibrinolysis and coagulation in humans.
British journal of haematology 2001;112(2):499-505.
2000: Wim H J Kruit; A M Eggermont; Gerrit Stoter
Interferon-alpha induced Raynaud's syndrome.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(11):1501-2.
2000: TC Stam; A J G Swaak; Wim H J Kruit; Gerrit Stoter; Alexander M M Eggermont
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.
European journal of clinical investigation 2000;30(4):336-43.
2000: C M L van Herpen; Rob L Jansen; Wim H J Kruit; Klaas Hoekman; Gerard Groenewegen; S Osanto; P H M De Mulder
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
British journal of cancer 2000;82(4):772-6.
1999: Johanna E A Portielje; Wim H J Kruit; Martin Schuler; J Beck; Cor H J Lamers; Gerrit Stoter; Christoph Huber; M de Boer-Dennert; A Rakhit; Reinder L H Bolhuis; Walter Aulitzky
Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):3983-9.
1999: Wim H J Kruit; P I M Schmitz; Gerrit Stoter
The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cells.
Cancer immunology, immunotherapy : CII 1999;48(6):331-5.
1999: L Berk; Arthur R Van Gool; Marjolein Bannink; Wim H J Kruit
[Side effects of interferon alfa].
Nederlands tijdschrift voor geneeskunde 1999;143(28):1461-4.
1999: Ronald de Wit; J van der Zee; M E L van der Burg; Wim H J Kruit; A Logmans; G C van Rhoon; Jaap Verweij
A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix.
British journal of cancer 1999;80(9):1387-91.
1998: Ronald de Wit; Wim H J Kruit; C H Lamers; Mars B van 't Veer; A A Luyten; V van Beurden; M Harteveld; A S T Planting; P I M Schmitz; Gerrit Stoter; Reinder L H Bolhuis; Jaap Verweij
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.
British journal of cancer 1998;77(12):2363-6.
1997: Wim H J Kruit; Swan Hoo Goey; C H Lamers; J W Gratama; B Visser; P I M Schmitz; A M Eggermont; Reinder L H Bolhuis; Gerrit Stoter
High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(4):312-20.
1997: Wim H J Kruit; Gerrit Stoter
The role of adoptive immunotherapy in solid cancers.
The Netherlands journal of medicine 1997;50(2):47-68.
1996: Ronald de Wit; Jaap Verweij; Marijke Bontenbal; Wim H J Kruit; C Seynaeve; P I M Schmitz; Gerrit Stoter
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
Journal of the National Cancer Institute 1996;88(19):1393-8.
1996: Wim H J Kruit; Cornelis J A Punt; Swan Hoo Goey; P H M De Mulder; J W Gratama; Alexander M M Eggermont; Reinder L H Bolhuis; Gerrit Stoter
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
British journal of cancer 1996;74(6):951-5.
1995: Wim H J Kruit; Swan Hoo Goey; F Calabresi; A Lindemann; R A Stahel; H Poliwoda; B Osterwalder; G Stoter
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
British journal of cancer 1995;71(6):1319-21.
1995: Marijke Bontenbal; A S T Planting; Jaap Verweij; Ronald de Wit; Wim H J Kruit; G Stoter; Jan G M Klijn
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.
Breast cancer research and treatment 1995;34(2):185-9.
1994: Wim H J Kruit; K J Punt; Swan Hoo Goey; P H M De Mulder; D C van Hoogenhuyze; S C Henzen-Logmans; G Stoter
Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication.
Cancer 1994;74(10):2850-6.
1993: Wim H J Kruit; Reinder L H Bolhuis; Swan Hoo Goey; R L Jansen; Alexander M M Eggermont; D Batchelor; P I M Schmitz; G Stoter
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):921-4.
1991: Wim H J Kruit; Swan Hoo Goey; J R Monson; R A Stahel; F Calabresi; R Mertelsmann; E E Holdener; Alexander M M Eggermont; Reinder L H Bolhuis; P H M De Mulder
Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.
British journal of haematology 1991;79 Suppl 1():84-6.